Loading…
← CockpitCompetitor Analysis › 6617.TWO Gongwin Biopharm Holdings Co., Ltd.Open in the cockpit ↗

Gongwin Biopharm Holdings Co., Ltd.6617.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Medical Distributors
Momentum leader 97
Mkt cap
$412M
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$2.23M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-27.9 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Close · TWDNT$116.50
1D-6.8%
1W-7.9%
1M-7.9%
3M+15.3%
6M+87.0%
YTD+35.3%
1Y+20.0%
ATR %7.0%
52w lowhigh21.8% off high

What Gongwin Biopharm does

No business profile yet.

Gongwin Biopharm at a glance

Size Gongwin Biopharm (6617.TWO) is a Taiwan Health Care company (Medical Distributors) with a market value of $412M, the 495th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$116.50 on 18 Nov 2026.

Performance Over six months the shares gained 87.0%, against -5.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 11.7% over the last twelve months (peer median +2.9%); the operating margin is -529.8% (peer median 2.3%).

Valuation It trades at 288.8× enterprise value to sales against a peer median of 1.1× (most expensive of 21).

Capital Return on invested capital runs 27.9 points below its cost of capital (5.0% WACC).

Relative performance

10015020021 May 202621 Aug 202618 Nov 20266617.TWO 179Peer median 94
Six months, rebased to 100: Gongwin Biopharm against the median of its 20 peers (local-currency closes).

Gongwin Biopharm financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$41.8MNT$36.4MNT$32.0MNT$18.9MNT$1.14M
Revenue growth—+14%+69%+1,555%—
Gross profitNT$15.0MNT$15.0M-NT$2.29M-NT$1.74M-NT$12.3M
EBITDA-NT$210M-NT$196M-NT$151M-NT$120M-NT$247M
Net income-NT$150M-NT$114M-NT$82.5M-NT$92.0M-NT$254M
Free cash flow-NT$189M-NT$138M-NT$293M-NT$112M-NT$240M
Capital expenditureNT$2.46MNT$2.46MNT$562MNT$123MNT$38.0M
Total debtNT$151MNT$130MNT$127MNT$77.2MNT$142M

Quarterly statements and history in the cockpit →

Gongwin Biopharm competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%000078410431516037166051363011663013707447000668600628688366ENTEROARJO-B603368DOCM74766617.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Gongwin Biopharm is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×100×200×00007841043151603716605136301166301370000668600628688366ENTERO6617.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Gongwin Biopharm is the large dot.

Gongwin Biopharm competitors and peer comparison

How Gongwin Biopharm compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Gongwin Biopharm against its 20 peers (data as of 18 Nov 2026)
Measure6617.TWOPeer medianRank in peer set
1-month return-7.9%-3.7%6th lowest of 21
6-month return+87.0%-5.6%2nd highest of 21
Distance from 52-week high-21.8%-21.1%11th highest of 21
Revenue growth (TTM)+11.7%+2.9%4th highest of 21
Operating margin-529.8%2.3%lowest of 21
EV / Sales288.8×1.1×most expensive of 21
ROIC minus cost of capital-27.9 pp-0.2 pplowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%288.8×n/an/a
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%0.6×58.3%-7.8%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%1.4×-1.2%+5.7%
Vital KSK 3151.TJapan$399M-1%+3%0%0.1×4.7%+2.6%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%4.3×n/an/a
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%1.1×21.1%-18.1%
Shanghai Universal Biotech 301166.SZChina$337M-15%+15%-4%1.0×n/an/a
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%0.7×13.1%+7.5%
Nagaileben 7447.TJapan$319M0%+1%21%1.6×-12.7%-0.4%
Rongfeng 000668.SZChina$297M-32%+61%14%4.8×9.6%+30.0%
Shanghai New World 600628.SSChina$573M-10%-2%6%2.1×-1.6%+1.0%
Arata 2733.TJapan$576M-3%+3%1%0.1×-6.2%+3.8%
Neuca NEU.WAPoland$795M-9%+8%2%0.3×5.3%+8.1%
Shanghai Haohai Biological Technology 688366.SSChina$878M-24%-9%-2%1.8×16.9%+13.2%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%1.2×24.7%+29.9%
Arjo ARJO-B.STSweden$974M+42%0%8%1.3×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%0.4×-9.7%+6.0%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%0.3×n/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%0.5×-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%1.0×n/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%1.3×0.0%+6.3%

Questions

Which companies are Gongwin Biopharm's closest peers?
The cockpit's peer set: Shenzhen Neptunus Bioengineering (000078.SZ), Excelsior Medical (4104.TW), Vital KSK (3151.T), Thalys Medical Technology (603716.SS), Shanghai Lily & Beauty Cosmetics (605136.SS), Shanghai Universal Biotech (301166.SZ), GKHT Medical Technology (301370.SZ), Nagaileben (7447.T).
Is Gongwin Biopharm expensive compared with its peers?
On ev / sales it trades at 288.8× against a peer median of 1.1×, most expensive of 21 in its peer set.
How has Gongwin Biopharm stock performed?
Over six months to 18 Nov 2026 the shares returned +87.0% against -5.6% for the median peer; over one year +20.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.